Taken together, our data suggest a strong impact of TLR9 on the initiation of T cell‐dependent arthritis, whereas its role in disease‐progression remains elusive as neither therapeutic application of a TLR9 antagonist nor lack of a functional TLR9 ameliorated PIA or serum‐transfer arthritis, respectively. This evidence concerns the gene TLR9 and arthritic joint disease.